Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106


The Novel RARβ Isoform (β 5) is a Potential Target of Retinoids in Breast Cancer

Author(s): Konstantin Christov.


Retinoic acid receptor beta 2 (RARβ2) isoform has been considered a putative tumor suppressor because it is expressed in normal cells but is lacking in most tumors, including breast cancer. Recently, we identified a novel RARβ isoform (β5) in breast cancer cells, which may sereve as a potential target of retinoids in cancer prevention and therapy studies. In this review are summarized the data on the expression of RARβ5 and of the previously identified RARβ4 and RARβ isoforms in various breast cancer cell lines. We found that RARβ5 may serve as a potential biomarker of resistance of breast cancer cells to retinoids and thus may have clinical implication in selecting patients that may benefit the most from clinical trials with retinoids.

Keywords: Retinoids, retinoid receptors, RARβ5 isoform, breast cancer, prevention

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Year: 2009
Page: [142 - 147]
Pages: 6
DOI: 10.2174/156800909787580953
Price: $58